SCHEMBL164622

SCHEMBL164622

O=C(O)NCCCc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.72
HPGD P15428 3/20 0.70
NPC1 O15118 3/20 0.70
RAB9A P51151 2/20 0.70
GAA P10253 1/20 0.70
EPHX2 P34913 1/20 0.68
KDM4E B2RXH2 2/20 0.66
POLB P06746 2/20 0.66
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 2/20 0.66
EPHX1 P07099 1/20 0.66
CYP2D6 P10635 1/20 0.66
KMT2A Q03164 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.65
CNR1 P21554 1/20 0.64
TAAR1 Q96RJ0 1/20 0.64
ALDH1A1 P00352 2/20 0.62
MAPT P10636 1/20 0.62
TSHR P16473 1/20 0.62
HTT P42858 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019835 0.94 TRPV1 (0.69) L3MBTL1HPGDNPC1RAB9AGAA
SCHEMBL893485 0.92 TRPV1 (0.72) L3MBTL1HPGDNPC1RAB9AGAA
SCHEMBL2024980 0.92 TRPV1 (0.72) L3MBTL1HPGDNPC1RAB9AGAA
SCHEMBL2021336 0.92 TRPV1 (0.72) L3MBTL1HPGDNPC1RAB9AGAA
SCHEMBL2021996 0.92 TRPV1 (0.72) L3MBTL1HPGDNPC1RAB9AGAA
SCHEMBL15861957 0.92 TRPV1 (0.72) L3MBTL1HPGDNPC1RAB9AGAA
SCHEMBL15093821 0.88 EPHX2 (0.86) L3MBTL1HPGDNPC1RAB9AGAA
Butylbenzyl SCHEMBL28335644 0.87 HPGD (0.62) L3MBTL1HPGDNPC1RAB9AGAA
Phenethylcarbamic Acid SCHEMBL249525 0.87 CA12 (0.68) L3MBTL1HPGDNPC1RAB9APOLB
SCHEMBL5932867 0.86 L3MBTL1 (0.70) L3MBTL1HPGDNPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367702-B2 Quinolone derivative ASTELLAS PHARMA INC. (JP) 2013-02-05 US claimed
US-20100256113-A1 QUINOLONE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-10-07 US claimed
EP-2194044-A1 QUINOLONE DERIVATIVE Astellas Pharma Inc. (JP) 2010-06-09 EP claimed
CN-1898234-A Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORP (US) 2007-01-17 CN claimed
EP-3527600-B1 ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER ASAHI CHEMICAL IND (JP) 2025-07-09 EP disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 EP disclosed
EP-4395763-A1 METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AXSOME THERAPEUTICS (US) 2024-07-10 EP disclosed
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains THE SCRIPPS RESEARCH INSTITUTE 2024-04-02 US disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
WO-2023233024-A1 DPP9 BINDING COMPOUNDS UNIVERSITEIT ANTWERPEN (BE) 2023-12-07 WO disclosed
US-20230114799-A1 ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-04-13 US disclosed
WO-2023034944-A1 METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AXSOME THERAPEUTICS (US) 2023-03-09 WO disclosed
CN-1366460-A Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as active ingredient SUNTORY LTD (JP) 2002-08-28 CN disclosed
CN-1366459-A Preventive and therapeutic agent for various diseases associated with eosinophilia comprising chymase inhibitor as active ingredient SUNTORY LTD (JP) 2002-08-28 CN disclosed
CN-1366461-A Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as active ingredient SUNTORY LTD (JP) 2002-08-28 CN disclosed
CN-1335778-A Blood vessel lipid deposition inhibitor containing chymotrypsin inhibitor SUNTORY LTD (JP) 2002-02-13 CN disclosed
US-5134151-A Platelet Activating Factor Antagonist J. URIACH & CIA (ES) 1992-07-28 US disclosed
EP-0385490-A1 2-picolylamine derivates J. URIACH & CIA. S.A. (ES) 1990-09-05 EP disclosed
US-4319018-A IN ACID CATALYST MITSUI TOATSU CHEMICALS, INC. (JP) 1982-03-09 US disclosed
US-4062862-A MUSCLE RELAXANT NIPPON CHEMIPHAR CO., LTD. (JA) 1977-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230114799-A1 ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER IDH3A, IDH2, IDH3B L3MBTL1 4577/4885HPGD 909/4885NPC1 1514/4885
US-20100256113-A1 QUINOLONE DERIVATIVE NQO1, NQO2, NADK L3MBTL1 2056/4885HPGD 43/4885NPC1 581/4885
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains TTR, MAP1LC3B, SAAL1 L3MBTL1 336/4885HPGD 3113/4885NPC1 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.